BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

· Issued by BioCryst Pharmaceuticals, Inc. via GlobeNewswire

On 6ix: 6ix.com/news/biocryst-begins-enrollment-in-pivotal-apex-p-trial-evaluating-orladeyor-berotralstat

Watch BioCryst Pharmaceuticals' latest callBiocryst Pharmaceuticals (NASDAQ:BCRX) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Biocryst Pharmaceuticals (NASDAQ:BCRX) Q2 2026 Earnings Call
BioCryst Pharmaceuticals' next earnings callBiocryst Pharmaceuticals (NASDAQ:BCRX) Q3 2026 Earnings Call · Nov 4, 2026 at 8:30 AM ESTRegister

RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial evaluating oral, once-daily ORLADEYO® (berotralstat) in pediatric hereditary angioedema (HAE) patients who are 2 to

BioCryst Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from BioCryst Pharmaceuticals

Later from BioCryst Pharmaceuticals

All BioCryst Pharmaceuticals news releases